Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CON, PDT, JVN

SUANFARMA announces a collaboration with Reyoung Pharmaceutical to expand the existing portfolio of anti-infective and antibacterial products

MADRID, Oct. 18, 2023 /PRNewswire/ -- SUANFARMA, through its R&D division, celebrates the historic agreement reached with Reyoung Pharmaceutical, a leader in the manufacture of active ingredients since 1966. Reyoung´s decades of experience as an exporter of products worldwide are perfectly aligned with SUANFARMA, which has been present in the pharmaceutical and nutritional ingredients market for 30 years.

This bilateral agreement between the Spanish multinational, providing the technology internally developed and its partner Reyoung with a well-known trustability in manufacturing capabilities, will constitute a strategic cooperation for anti-infective and antibacterial API production. These drugs are crucial to guaranteeing the health of the population. Both companies consider it essential to ensure the supply of this therapeutic line, especially in these times of shortages and increased supply chain uncertainty for the global pharma industry.

SUANFARMA is committed to health and innovation, which is why it develops and produces accessible raw materials in accordance with the highest regulatory requirements of the EMA or the FDA. Moreover, the company is also devoted to environmentally responsible practices, embracing green chemistry and prioritizing environmental protection. To this end, their robust R&D team works on the development of technologies to achieve maximum efficiency in its processes, to incorporate cutting-edge active ingredients into its portfolio.

The innovative technology developed by SUANFARMA involves Flow Chemistry, improving yields, selectivity and reproducibility of the processes. It minimizes reaction times and requires smaller quantities of reagents and solvents, reducing raw material use and environmental impact. In addition, this technique is generally safer than traditional synthesis, reducing the risk of explosions and leaks of hazardous reagents.

"We are thrilled to join forces with SUANFARMA as we embark on this transformative collaboration, which marries innovation with exceptional product delivery. This alliance marks the beginning of an exciting journey, and we are confident that our collaboration will deliver immense value to our customers and partners by harnessing the unique strengths and capabilities of each organization", declares Mr. Xie- Reyoung Pharmaceutical Vice-President

"This important strategic agreement between Reyoung and SUANFARMA highlights our shared commitment to technology-driven innovation and maximizing efficiency in order to provide superior products to the patients. Reyoung's exceptional partnership as our ally strengthens our global position, marking the first milestone in what we anticipate will be an immensely promising collaboration between our organizations", says Javier Calvo, SUANFARMA R&D Director.

This significant agreement is expected to be the beginning of a strong with very promising results for the benefit of the patients.

We are fully committed to enhancing the health of both humans and animals, striving to prevent diseases in a sustainable manner.


SUANFARMA founded in 1993, is a B2B life science partner specialized in the development, production, and commercialization of ingredients for the pharmaceutical, veterinary and nutraceutical industries.

About Reyoung

Reyoung is a modern, vertically integrated pharmaceutical company, focused on enhancing the quality of its products by using innovation as the basis of the process.

Photo - https://mma.prnewswire.com/media/2248559/Reyoung_SUANFARMA.jpg
Logo - https://mma.prnewswire.com/media/2234752/4343535/Suanfarma_Logo.jpg

These press releases may also interest you

at 02:05
ViroCell Biologics ("ViroCell" or the "Company") a cell and gene therapy ("CGT") contract development and manufacturing organization ("CDMO") specializing in GMP viral vector manufacturing for clinical trials, announces the signing of a five-year...

at 01:45
Delivering our highest ever quarterly sales amounting to USD 217 millionOrganic growth of 6% for Q2 driven strong performance in Prosthetics & Neuro Orthotics and Patient CareEBITDA was USD 47 million and EBITDA margin was 22% for Q2Medicare in the...

at 01:35
Regulatory News: Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces...

at 01:35
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system...

at 01:30
XRP Healthcare, a pioneering company integrating blockchain technology with healthcare services, has announced the cessation of new staking activities for its XRPH token. This strategic move aims to safeguard the finite supply of the token, which was...

at 00:00
Cytoki Pharma, ApS (Cytoki), a clinical-stage biotechnology company pioneering a new class of medicines that harness IL-22 biology to drive improved outcomes for metabolic disease, today...

News published on and distributed by: